AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

We reviewed evidence on the effectiveness of high-flow nasal cannula (HFNC) therapy in supporting children's breathing. We found 11 studies in children. HFNC therapy delivers a mixture of air and ...